We studied 35 otherwise healthy adults with frequently recurring genital herpes (greater than or equal to 1 episode per month), in a double-blind trial comparing oral acyclovir with placebo capsules for suppression of recurrent infection. The patients were treated for 125 days unless herpes recurred. Among 32 evaluable patients, there were significantly fewer recurrences during acyclovir treatment (4 of 16) than during placebo treatment (16 of 16, P less than 0.001). The mean duration of therapy was significantly longer for patients receiving acyclovir than for those receiving placebo (114.9 vs. 24.8 days, P less than 0.001). Of 19 patients who had recurrences in the blind trial, only 2 had recurrences when given acyclovir in a second, open-study phase. All patients had recurrences after completing acyclovir treatment. The therapy was well tolerated, with minimal gastrointestinal upset and one hypersensitivity reaction. Studies of the viral isolates demonstrated that lesions developing in patients receiving acyclovir contained drug-resistant virus. Later recurrences in these patients were associated with drug-sensitive virus. We conclude that oral acyclovir suppresses genital herpes in patients with frequent recurrences, but the potential for problems with drug resistance and the long-term safety need to be more fully explored.
This article has been cited by other articles:
Cernik, C., Gallina, K., Brodell, R. T.
(2008). The Treatment of Herpes Simplex Infections: An Evidence-Based Review. Arch Intern Med
168: 1137-1144
[Abstract][Full Text]
Fife, K. H., Meng, T.-C., Ferris, D. G., Liu, P.
(2008). Effect of Resiquimod 0.01% Gel on Lesion Healing and Viral Shedding When Applied to Genital Herpes Lesions. Antimicrob. Agents Chemother.
52: 477-482
[Abstract][Full Text]
Bacon, T. H., Levin, M. J., Leary, J. J., Sarisky, R. T., Sutton, D.
(2003). Herpes Simplex Virus Resistance to Acyclovir and Penciclovir after Two Decades of Antiviral Therapy. Clin. Microbiol. Rev.
16: 114-128
[Abstract][Full Text]
Schacker, T. W., Conant, M., Thoming, C., Stanczak, T., Wang, Z., Smith, M.
(2002). Imiquimod 5-Percent Cream Does Not Alter the Natural History of Recurrent Herpes Genitalis: a Phase II, Randomized, Double-Blind, Placebo-Controlled Study. Antimicrob. Agents Chemother.
46: 3243-3248
[Abstract][Full Text]
Lipsitch, M., Bacon, T. H., Leary, J. J., Antia, R., Levin, B. R.
(2000). Effects of Antiviral Usage on Transmission Dynamics of Herpes Simplex Virus Type 1 and on Antiviral Resistance: Predictions of Mathematical Models. Antimicrob. Agents Chemother.
44: 2824-2835
[Abstract][Full Text]
Mindel, A, Taylor, J, Tideman, R L, Seifert, C, Berry, G, Wagner, K, Page, J, Marks, C, Trudinger, B, Cunningham, A
(2000). Neonatal herpes prevention: a minor public health problem in some communities. Sex. Transm. Infect.
76: 287-291
[Abstract][Full Text]
Benedetti, J. K., Zeh, J., Corey, L.
(1999). Clinical Reactivation of Genital Herpes Simplex Virus Infection Decreases in Frequency over Time. ANN INTERN MED
131: 14-20
[Abstract][Full Text]
Ashley, R. L., Wald, A.
(1999). Genital Herpes: Review of the Epidemic and Potential Use of Type-Specific Serology. Clin. Microbiol. Rev.
12: 1-8
[Abstract][Full Text]
Diaz-Mitoma, F., Sibbald, R. G., Shafran, S. D., Boon, R., Saltzman, R. L., for the Collaborative Famciclovir Genital Herpes R,
(1998). Oral Famciclovir for the Suppression of Recurrent Genital Herpes: A Randomized Controlled Trial. JAMA
280: 887-892
[Abstract][Full Text]
Bachman, D. M., Barron, B. A.
(1998). Prevention of Herpes Simplex Keratitis and Iritis. Arch Ophthalmol
116: 259-259
[Full Text]
Kost, R. G., Hill, E. L., Tigges, M., Straus, S. E.
(1993). Recurrent Acyclovir-Resistant Genital Herpes in an Immunocompetent Patient. NEJM
329: 1777-1782
[Full Text]
Dolin, R
(1985). Antiviral chemotherapy and chemoprophylaxis. Science
227: 1296-1303
[Abstract]
